Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Karyopharm Therapeutics Inc
KPTI
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.5461
0.12
28.68%
Ult. Agg.: Oct 22, 7:59 PM
$0.5316
0.11
25.26%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Karyopharm Therapeutics Financials
Karyopharm Therapeutics (KPTI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
Benzinga Newsdesk
PRO
Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate
Benzinga Newsdesk
PRO
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $137.489 million estimate.
Benzinga Newsdesk
PRO
Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.40) by 11.43 percent. This is a 55.23 percent increase over losses of $(2.77) per
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
PRO
UPDATE: Karyopharm Therapeutics Q4 Adj. EPS $(2.23) Misses $(1.99) Estimate
Benzinga Newsdesk
